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Article

Ovarian cancer progression is controlled
by phenotypic changes in dendritic cells
Uciane K. Scarlett,1 Melanie R. Rutkowski,1 Adam M. Rauwerdink,2
Jennifer Fields,3 Ximena Escovar-Fadul,1 Jason Baird,4
Juan R. Cubillos-Ruiz,4 Ana C. Jacobs,4 Jorge L. Gonzalez,5
John Weaver,2 Steven Fiering,3,4 and Jose R. Conejo-Garcia1
1Immunology

Program, the Wistar Institute, Philadelphia, PA 19104
of Radiology, 3Department of Genetics, 4Department of Microbiology and Immunology,
and 5Department of Pathology, Dartmouth Medical School, Lebanon, NH 03756

The Journal of Experimental Medicine
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We characterized the initiation and evolution of the immune response against a new inducible p53-dependent model of aggressive ovarian carcinoma that recapitulates the leukocyte
infiltrates and cytokine milieu of advanced human tumors. Unlike other models that initiate
tumors before the development of a mature immune system, we detect measurable antitumor immunity from very early stages, which is driven by infiltrating dendritic cells (DCs)
and prevents steady tumor growth for prolonged periods. Coinciding with a phenotypic
switch in expanding DC infiltrates, tumors aggressively progress to terminal disease in a
comparatively short time. Notably, tumor cells remain immunogenic at advanced stages, but
anti-tumor T cells become less responsive, whereas their enduring activity is abrogated by
different microenvironmental immunosuppressive DCs. Correspondingly, depleting DCs early
in the disease course accelerates tumor expansion, but DC depletion at advanced stages
significantly delays aggressive malignant progression. Our results indicate that phenotypically divergent DCs drive both immunosurveillance and accelerated malignant growth. We
provide experimental support for the cancer immunoediting hypothesis, but we also show
that aggressive cancer progression after a comparatively long latency period is primarily
driven by the mobilization of immunosuppressive microenvironmental leukocytes, rather
than loss of tumor immunogenicity.
CORRESPONDENCE
Jose R. Conejo-Garcia:
jrconejo@wistar.org
Abbreviations used: DLN,
draining LN; IOSE, immortalized ovarian surface epithelial.

Epithelial ovarian cancer is a devastating disease
responsible for the deaths of 15,000 Americans
per year, even more than melanoma or brain
tumors (Jemal et al., 2009). Independent studies
have demonstrated that in the ovarian carcinoma microenvironment, T cells (and only they)
can spontaneously exert clinically relevant pressure against tumor progression (Zhang et al., 2003;
Sato et al., 2005; Hamanishi et al., 2007). However, as the dismal statistics show, immune pressure
against established tumors is insufficient. In part,
this is because when tumors become clinically
symptomatic, they have already overcome the
immune system through multiple complementary mechanisms. The “cancer immunoediting”
hypothesis, supported by recent experimental and
clinical evidence, provides a frame to understand
this process (Schreiber et al., 2011). The model
implies that all symptomatic tumors represent a
failure of the immune system. Recent studies
have postulated that tumors can be kept in check
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for long periods, through a dynamic balance
that results in the progressive loss of immunogenicity by tumor cells. However, emerging clinical
evidence from multiple trials blocking common
immunosuppressive checkpoints (such as CTLA4
or PD-1) indicates that preventing tumor-induced
T cell paralysis restores protective immunity
against established cancers, implying that advanced
tumors remain somewhat immunogenic. Based
on multiple lines of evidence, the model has
recently evolved to include the role of immunosuppression in the tumor microenvironment in
this process. However, the relative contribution of
individual microenvironmental populations to
suppress or support the capacity of tumors to
expand and their dynamics remains unclear.
© 2012 Scarlett et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.rupress.org/terms). After six months
it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons
.org/licenses/by-nc-sa/3.0/).
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Some excellent non-transplantable models of ovarian cancer
are available, but mutagenic events activated during embryonic
development result in animals that are born with premalignant
lesions (Connolly et al., 2003; Xing et al., 2009), which complicates their use for understanding tumor initiation. For instance,
seminal studies by Clark et al. (2007), using a genetic model of
pancreatic cancer, found immune tolerance against cancer soon
after birth. This may reflect the distinctive physiopathology of
pancreatic cancer but also be the result of defective immunosurveillance when mutations are initiated before the development
of a mature immune system.
To understand how the evolution of the inflammatory
microenvironment of developing aggressive ovarian cancers
influences tumor progression, we have generated a new p53dependent model that recapitulates the immune populations
of human tumors in previously healthy hosts. Our results
show that accelerated malignant progression after a relatively
long period of immune control is triggered by a phenotypic
switch in expanding DC infiltrates, which can be reversed
upon DC depletion, without specifically ablating tumor cells.
RESULTS
Generation of a p53-dependent inducible
metastatic ovarian carcinoma
To model the immunobiology of aggressive (type II) ovarian
cancers (Kurman and Shih, 2011), we first sought to generate
an inducible cancer model in previously healthy adult mice,
avoiding the initiation of carcinogenic events before the
development of a mature immune system. For that purpose,
496

Figure 1. The p53-dependent mouse
model of ovarian carcinoma develops solid
peritoneal tumor masses. (A) Expression of
KRAS mRNA (normalized to GAPDH) in 17 representative cases of stage III–IV human ovarian
carcinomas, relative to IOSE cells (immortalized
cells from the normal ovarian epithelial surface).
(B) Relative protein expression of K-ras (normalized to -actin) in seven randomly selected
stage III–IV human ovarian carcinoma specimens, IOSE cells, or HOSEpiC cells (healthy ovarian epithelial cells cryopreserved either at
primary or passage one cultures). (C) Injection of
trypan blue into the bursal cavity of transgenic
mice. (D) Intrabursal adenoviral injection in p53/
K-ras mice results in a primary solid ovarian
tumor mass (P) with accompanying metastatic
lesion (M). U, uterus. (E) Ascites detected in the
peritoneal cavity of a chimeric p53/K-ras mouse
injected with the adenovirus 50 d before.
(F) Primary (P) and spontaneous metastatic
masses (white arrows) in p53/K-ras mice 50 d
after receiving adenovirus. (G) H&E of metastatic
masses from indicated regions which appeared
in mice 3 mo after undergoing resection of
primary tumors at 35 d. Black arrows indicate
tumor tissue. Bars, 100 µm. (H) p53/K-ras
primary epithelial tumors stained for Cytokeratin 8 (CK8; ×100), Pan-Cytokeratin (PanCK;
×200), smooth muscle actin (SMA; ×100); and
Vimentin (×100). Bars, 100 µm. Brightness, contrast, and color balance were uniformly adjusted
in whole individual images.

we used a previously
described technique
(Flesken-Nikitin et al.,
2003; Dinulescu et al.,
2005), based on the delivery of recombinant adenoviruses expressing Cre recombinase into the ovarian bursal cavity. Ablation
of only p53—the hallmark of malignancy in human ovarian
carcinoma (Bernardini et al., 2010)—did not result in any obvious carcinogenic event >200 d after induction of the mutation (not depicted).To add a relevant second mutagenic event,
we investigated the occurrence of KRAS deregulation in a
cohort of 60 unselected stage III–IV human ovarian carcinoma
specimens. We found highly variable levels of KRAS mRNA
in both metastatic and primary specimens, but all were higher
than the very low levels of an immortalized ovarian surface
epithelial (IOSE) cell line (Wang et al., 2006; Fig. 1 A). Most
importantly, KRAS protein was also dramatically overexpressed
in multiple tumors, compared with IOSE cells or HOSEpiC
epithelial cells from healthy ovaries cryopreserved either at
primary or passage one cultures (Fig. 1 B), indicating that, beyond the frequent gene amplification recently reported by
the Cancer Genome Atlas Network (Bell et al., 2011), KRAS
is deregulated in most advanced human ovarian cancers.
To model the constitutive activation of KRAS, we took advantage of existing LSL-K-rasG12D/+ mice (Jackson et al., 2001).
Intrabursal delivery makes injected materials accessible to both
the epithelial surface and the fimbriated epithelium at the interphase with the oviduct (Fig. 1 C). Concurrent ablation of
p53 and activation of oncogenic K-ras in double (p53/K-ras)
DCs influence ovarian cancer progression | Scarlett et al.
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Figure 2. The inflammatory microenvironment of p53/K-ras end-stage tumors recapitulates advanced human ovarian carcinoma. (A) Quantification at the indicated time points of cells found within the ovaries of WT animals (n = 8) after receiving adenovirus intrabursally. Gated on CD45+ cells.
(B) Expression of indicated activation markers on CD45+CD11c+ DCs taken from tumors or DLN of p53/K-ras mice. Early, 7 d after AdvCre injection;
Advanced, mice with advanced tumors. Representative density plots of dissociated tumors from p53/K-ras mice (C) and patients with stage III–IV ovarian
carcinoma (gated on CD45; D). (E–G) Density flow plots of dissociated tumors from individual patients with stage III–IV ovarian carcinoma. (H) Gating
strategy (above) and isotypes (below) for Table 1. Error bars, SEM.

transgenic mice then resulted in palpable abdominal tumor lesions with 100% penetrance only 35 d after adenoviral administration. Tumors were found to be perfectly solid as they
became more advanced (Fig. 1 D). In a proportion of animals
we detected gross hemorrhagic ascites (Fig. 1 E), as well as metastases at multiple peritoneal locations (Fig. 1, F and G).
Histological sections of the primary and metastatic tumor
sites revealed a growth pattern characterized by solid masses
comprised of malignant spindled cells with interspersed large
anaplastic tumor cells. The neoplastic cells were immuno
reactive for cytokeratin 8, desmin (not depicted), and smooth
muscle actin and were negative for vimentin (Fig. 1 H).
Patchy immunoreactivity with a pan-cytokeratin antibody
cocktail was also noted (Fig. 1 H). Although on a morphological basis, sarcoma is a consideration, the immunohistochemical staining pattern is most consistent with sarcomatoid
ovarian carcinoma (i.e., induction of a high-grade poorly
differentiated ovarian carcinoma with spindle cell morphology). Together, these data indicate that concurrent p53 and
K-ras mutations in the epithelial ovarian surface and/or fimbriated epithelium at the interphase with the oviduct result
in highly metastatic tumors with complete penetrance and
short latency.
JEM Vol. 209, No. 3

Inducible ovarian tumors recapitulate the inflammatory
microenvironment of human ovarian cancer
Nonreplicating adenoviral-Cre delivery in WT mice altered
the leukocytic ovarian microenvironment only in a temporary
manner, as the proportions of tissue-resident CD11c+ DCs
were unchanged between 1 and 5 wk after surgical manipulation (Fig. 2 A). Ovarian T cell infiltration (the other predominant leukocyte subset in healthy ovaries) was similarly
unaffected (Fig. 2 A). However, when we performed an exhaustive phenotypic analysis of the immune microenvironment of
solid advanced p53/K-ras tumor masses, we found a relatively
homogeneous population of CD11c+DEC205+MHC-II+
CD11b+CD86CD40low DCs, supporting our previous ob
servations in transplantable models (Scarlett et al., 2009;
Fig. 2, B and C). These populations of DCs expressing low
levels of co-stimulatory molecules were also present in tumor
draining LNs (DLNs) of animals with end stage tumors (Fig. 2 B).
Most importantly, terminal tumors recapitulated the immune
microenvironment of advanced human ovarian carcinomas,
including a heterogeneous mix of antigen-presenting cells
(Wilke et al., 2011). Thus, in advanced solid tumors of humans and p53/K-ras mice, the predominant leukocyte subset
expressed phenotypic markers of bona fide DCs, including
497

Table 1.

Flow analysis of leukocytes infiltrating solid Stage III/IV human ovarian tumors

Patients

S1 Patient 1
S2 Patient 2
S4 Patient 3 (P)
S5 Patient 3 (M)
S6 Patient 4
S7 Patient 5
S8 Patient 6
S9 Patient 7
S10 Patient 8
S11 Patient 9
S12 Patient 10

Gated on CD45

Gated on CD11c+HLA-DR+

Gated on Dec205

Gated on CD45

CD11c+

CD11c+HLA-DR+

Dec205+

Dec205

CD11b+CD14+

CD20+

CD3+

52
47.2
84.7
84.8
12
57.1
52.8
41.7
28.2
37.2
37.1

30.9
47.1
82.2
56.3
12.3
56.5
52.4
40
6.35
36.5
5.4

39.9
59.1
17.2
12
70.3
70.3
41.3
n/a
n/a
n/a
n/a

61.7
39.4
81.2
76.8
30.1
25.8
59.9
n/a
n/a
n/a
n/a

28.6
29.2
4.9
15.6
44.5
21.5
7.04
n/a
n/a
n/a
n/a

1.78
2.79
n/a
n/a
n/a
n/a
1.78
0.27
0.013
2.85
0.045

30.9
45.7
n/a
n/a
n/a
n/a
30.9
10.2
0.49
8.34
1.92

Gating strategy is outlined in Fig. 2 H. n/a, insufficient material. Values are expressed as percentages.

CD11c, DEC205, and MHC-II (Fig. 2, C and D). In humans,
the precise categorization of solid tumor-infiltrating myeloid leukocytes was more complicated as the result of a
high degree of phenotypic overlap between DCs and macrophages in some specimens. However, the most abundant
leukocyte in at least a third of the specimens analyzed clearly
lacked the monocyte/macrophage markers CD11b or CD14
but coexpressed the DC marker CD11c (Fig. 2, E–G; and
Table 1). These cells also maintain a high level of expression
of MHC-II, so they cannot be alternatively defined as more
immature myeloid-derived suppressor cells (Nagaraj and
Gabrilovich, 2010; Fig. 2 H and Table 1). Interestingly, DCs
in our mouse model progressively down-regulated MHC-II
expression until 35 d, whereas DCs found within advanced
tumors (>50 d) showed intermediate MHC-II expression.
In contrast, the microenvironment of ascites showed the
presence of predominant bona fide macrophages (Fig. 2 G).
Therefore, the distinctive product of excessive myelopoiesis
in most human ovarian cancer solid tumor masses is a leukocyte with predominant phenotypic attributes of DCs,
rather than canonical macrophages, which is recapitulated
in our animal model.

Besides corresponding expression of phenotypic determinants, CD45+CD11c+MHC-II+ DCs sorted from dissociated
p53/K-ras advanced tumors and CD45+CD11chiHLA-DRhiDec205int from unselected human tumor specimens responded
to PMA and ionomycin by secreting a comparable pattern of
proinflammatory chemokines. Those included high levels of
CCL3 and CCL4, in addition to pro-angiogenic IL-8/KC
(Fig. 3 A). A similar cytokine profile was found in DCs sorted
from a transplantable mouse model of ovarian cancer (ID8Debf29/Vegf-A; Fig. 3 A). Together, these data indicate that
our p53-dependent tumor model faithfully recapitulates the
immune microenvironment of human ovarian cancer, and it is
therefore suitable to understand its unknown dynamics.
Accelerated tumor growth after prolonged stability
coincides with a switch in the inflammatory infiltrate
We found that, starting after day 21 after the adenovirus-Cre
challenge, tumors accumulated progressively denser immune
cell infiltrates (Fig. 3, B and C). Remarkably, tumor progressed
through a prolonged equilibrium phase for 28 d, when no
obvious macroscopic masses were detectable (Fig. 4 A, top).
Leukocytes other than DCs in tumor-developing ovaries at

Figure 3. DCs found within solid p53/
K-ras tumors display similar proinflammatory
attributes as human tumor-derived DCs.
(A) Quantification of cytokines and chemokines
secreted from sorted CD45+CD11c+Dec205+C
D11b+/ cells from advanced human tumor
specimens (n = 3) or CD45+CD11c+CD11b+
cells from tumors of end-stage p53/K-ras
mice (n = 4) or ascites of WT mice bearing
ID8-Defb29/Vegf-a tumors. (B) Proportion of
CD45+ cells found within the ovaries of p53/
K-ras mice (n = 6) at the indicated time points
after adenovirus injection. (C) CD45 immuno
histochemical analysis of resected tumors
(>50 d) ×100. Error bars, SEM. Bar, 100 µm.
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Figure 4. A change in the inflammatory microenvironment converges with the exponential growth of p53/K-ras tumors. (A) Top, images of explanted
reproductive organs from p53/K-ras mice after receiving adenovirus. Middle and bottom, quantified flow analysis of resected tumors (red circle; primordial and
advanced) from p53/K-ras (middle; n = 4–6) and WT (bottom; n = 6–8) animals, which received adenovirus previously. Slices represent mean percentages of
CD45+ leukocytic infiltrates. (B) Comparative analysis of CD45+CD11c+CD11b and CD45+CD3+ cells infiltrating tumors of p53/K-ras mice at the indicated time
points (n = 4–8). (C) Density plots of p53/K-ras tumors or WT ovaries which received adenovirus 35 d before (gated on CD45+ cells). Histogram of CD45+F4/
80+CD11c (blue) and CD45+CD11c+F4/80 (red). Numbers in the right corner are respective mean fluorescence intensity (MFI). (D) Percentage of CD45+CD11c+
and CD45+CD3+ cells found within stage III/IV human ovarian carcinoma (n = 7). (E and F) Quantification of flow analysis at the indicated time points of ovaries
from p53/K-ras (n = 4–6) or WT (n = 6–8) mice after adenovirus injection. Error bars, SEM. *, P < 0.05; **, P < 0.001; ***, P < 0.0001; ns, no significance).

this stage did not significantly differ from surgically treated
ovaries in WT mice, and they were characterized by predominant T cell infiltrates after day 7 (Fig. 4, A [bottom] and B).
Approximately 35 d after adenoviral challenge, coinciding
with a change in the ratio of T cells versus DCs (Fig. 4,A and B),
palpable tumors become apparent. At this time, these leukocytes show predominant phenotypic determinants of the DC
lineage, as they express DEC205 and CD11c (Fig. 4 C) as well
as MHC-II. In contrast, these leukocytes did not express the
macrophage marker F4/80 (Fig. 4 C) and still lacked expression of the myeloid marker CD11b (Fig. 4 E). We also found
comparable ratios of CD11c leukocytes to T cells in advanced
JEM Vol. 209, No. 3

human tumor specimens (Fig. 4 D). From this critical turning
point at 28 d, tumors started growing aggressively, and mice
needed to be sacrificed at 60 d (Fig. 4 A). Notably, inflammatory infiltrates during this exponential phase predominantly
expanded by accumulating CD11c+ cells, which outnumbered
lymphocytes and remained the most abundant leukocytic
subset until terminal stages (Fig. 4, A [middle], E, and F). This
dramatic change in infiltrating leukocytes was not observed
in WT animals, which were similarly treated with adenovirusCre, and is therefore not a result of viral clearance or resolution of inflammation (Fig. 4, A [bottom], E, and F).Therefore,
inducible p53/K-ras–dependent ovarian cancer progresses
499

Figure 5. Reduced adaptive immunity during accelerated tumor growth. (A) Representative images of differential tumor burden (primary
plus metastatic growth) in mice challenged with
intrabursal adenovirus-Cre that received de
pleting anti-CD8 (-CD8) versus isotype control
(iIgG) antibodies at days 2, 5, 12, and 19
(n = 4/group). (B) Left, ELISPOT analysis of IFN-
produced by FACS-sorted CD45+CD11bCD11c
SSClowCD8+/CD4+ T cell splenocytes incubated with
tumor pulsed BMDCs (10:1). Spleens are from
either WT or p53/K-ras (early) animals that received
adenovirus-Cre intrabursally 7 d before (n = 5
mice/group; two independent experiments).
Middle, quantified proliferation of sorted T cell
splenocytes from early tumor-bearing p53/K-ras
or WT animals in response to BMDC-presented
tumor antigens (n ≥ 5 mice/group; two independent experiments). Right, representative histogram of CFSE dilution in this experiment. (C) Left,
ELISPOT analysis of Granzyme B (GZB) produced
by CD45+CD11bCD11cSSClowCD8+/CD4+
T cells FACS sorted from DLNs (renal) from the
same mice, after incubation with tumor pulsed
BMDCs (10:1). Middle, quantified proliferation
of these lymphatic T cells in response to BMDCpresented tumor antigens. (D) Percentage of
IFN- spots produced by CD45+CD11bCD11c
SSClowCD8+/CD4+ T cells sorted from the DLN
of either WT mice that received adenovirus 7 d
before, or p53/K-ras advanced tumor-bearing
mice. Normalized to the number of spots produced by sorted DLN T cells from day 7 (early)
tumor-bearing mice, which is considered 100%
(n ≥ 4 mice/group; pooled from two independent
experiments). (E) Left, ELISPOT analysis of IFN-
produced by CD45+CD11bCD11cSSClowCD8+/
CD4+ T cells sorted from the DLN of p53/K-ras animals that received adenovirus-Cre intrabursally either 7 d (early) or >50 d (advanced) before. Middle, quantified
proliferation of sorted T cells from the same mice in response to BMDC-presented tumor antigens (n = 3 mice/group; three independent experiments, total). Right,
representative histogram of CFSE dilution in this experiment. Error bars, SEM. *, P < 0.05. Data points on scatter plots represent individual donors for spleens and
experimental replicates for pooled DLN. Horizontal bars, SEM. Two independent experiments for all, unless otherwise specified.

through a state of equilibrium that keeps tumor expansion in
check for the first 4 wk, followed by a phase of aggressive
growth that coincides with a dramatic switch in the signature
of tumor-infiltrating leukocytes.
Early anti-tumor immunity is abrogated
during aggressive malignant expansion
Notably, antibody-mediated depletion of CD8+ T cells dramatically accelerated aggressive malignant expansion and enhanced tumor burden compared with control mice, which
did not develop any extra-ovarian masses at this temporal
point and grew smaller primary tumors (Fig. 5 A). Tumor
progression in our model therefore both supports and
illustrates the cancer immunoediting hypothesis, whereby
tumor growth can be controlled by the immune system until
tumor cells escape, producing symptomatic cancers (Dunn
et al., 2002; Koebel et al., 2007). To identify whether primordial tumor lesions truly elicit specific immune responses,
500

we performed ELISPOT analysis with T cells sorted from
mice developing early tumors. As early as at day 7 of tumor
progression, sorted splenic T cells specifically reacted to tumor
antigen presented by immunocompetent DCs by proliferating and secreting IFN- (Fig. 5 B, left). Importantly, these
responses were specific for tumor antigens and not the adenovirus because they were absent or significantly diminished
when T cells were sorted from WT (non–tumor-bearing)
mice identically inoculated with intrabursal adenovirus-Cre
(Fig. 5 B). Differential tumor-specific responses indicative
of cytolytic T cells (Granzyme B ELISPOT analysis) were
also observed between WT and transgenic mice using T cells
sorted from DLNs (renal; Fig. 5 C), with corresponding
differences in proliferation in response to tumor antigens
(Fig. 5 C) and IFN- ELISPOT analysis (Fig. 5 D). Importantly, these data indicate that advanced tumors remain
immunogenic because all lysates used were from late tumors
(early tumors are microscopic). In these experiments, T cells
DCs influence ovarian cancer progression | Scarlett et al.
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Figure 6. Tumor-resident DCs are transformed from immunostimulatory to immunosuppressive during tumor progression. (A) Left, CD3+ T cells
were obtained from spleens of advanced tumor-bearing p53/K-ras animals, and then added to cultures containing BMDCs (10:1) which were previously
pulsed with lysed tumor cells. 5 d later, sorted (nonpulsed) CD45+CD11c+ DCs from the DLNs or tumors (tumor-infiltrating DCs; TIDCs) were co-cultured
with the tumor-specific CD3+ T cells, after CFSE labeling (10:1). Right, percentage of proliferated T cells which were cultured with sorted DCs from the DLN
of mice with advanced tumors or animals with primordial tumors (early; received adenovirus 7 d before) or DCs from advanced tumors (B). (C) ELISPOT
analysis of the responses induced by CD45+CD11c+ DCs, sorted from the spleens of early and advanced tumor-bearing mice, and directly incubated with tumorreactive T cells, obtained as in A. (D) Tumor-specific CD3+ T cells were obtained as in A, and then added to culture wells, which contained tumor pulsed
BMDCs (1:1). Either sorted CD45+CD11c+CD11b+/ DCs or unpulsed BMDCs were added to these cultures making a 1:1:1 ratio (T cell/pulsed BMDC/sorted
DC/BMDC). (E) Left, proliferation indices of T cells in response to the addition of tumor infiltrating DCs (TIDCs) or BMDCs. Right, representative histogram of
CFSE dye dilution. (F) Left, proliferation indices of T cells in response to the addition of BMDCs or DLN DCs sorted from mice with early or advanced tumors.
Right, representative histogram of CFSE dilution. n = 4 mice/group. BMDC cultures were done in quad- or quintuplicate. Even stronger differences were
obtained using all tumor-pulsed BMDCs (not depicted). Error bars, SEM. Data points on scatter plots represent experimental replicates for pooled DLN or
tumors. Horizontal bars, SEM. *, P < 0.05. Representative of at least two independent experiments in all panels (n = 3–4 mice/group).

sorted from early tumor-bearing mice reacted against
BMDCs pulsed with lysates of tumor cells derived from
advanced (>60 d) specimens. However, T cells sorted from
the DLNs of advanced (>50 d) tumor-bearing mice produced significantly fewer IFN- spots in response to the
same antigens (Fig. 5, D and E, left). T cell unresponsiveness at advanced stages was further confirmed by diminished proliferative responses in response to the same tumor
antigens (Fig. 5 E, middle and right). Because DCs pulsed
with cells derived from advanced tumors induced significant proliferative responses in early tumor-associated T cells,
these data demonstrate that tumor-specific T cells become
intrinsically less responsive during advanced malignant
progression. Therefore, T cell–dependent tumor-specific immune responses are elicited from a very early stage after
tumor initiation, but they are abrogated during the course
of the disease.
JEM Vol. 209, No. 3

Immunostimulatory antigen-presenting cells in primordial
tumor lesions are replaced by immunosuppressive DCs
in advanced ovarian cancer
The cancer immunoediting hypothesis has recently evolved to
include a role for tumor-induced immunosuppression in accelerated tumor growth (Schreiber et al., 2011). However, the
relative contribution of specific tolerogenic mechanisms in individual tumors remains unknown. To determine how phenotypic changes in tumor microenvironmental leukocytes drive
the transition from equilibrium to accelerated tumor growth
and influence anti-tumor T cell unresponsiveness, we first analyzed the immunostimulatory potential of CD11c+ DCs sorted
from the DLNs of primordial (day 7) tumor lesions (Fig. 6 A).
In agreement with the quantifiable anti-tumor immunity taking place at this time, we found that DCs from early tumorbearing mice, in the absence of exogenous antigen, induced
measurable expansion in tumor-reactive T cells taken from
501

Figure 7. Tumor-infiltrating DCs exhibit a tolerogenic phenotype. (A) Mean fluorescent intensity (MFI) of CD40, MHCII, and PD-L1 on CD45+CD11c+
DCs from early (ovaries 7 d after adenovirus injection) or advanced tumor masses (n = 4/group). (B) Arginase activity of CD45+CD11c+ cells sorted from
advanced dissociated tumors and spleens of p53/K-ras animals (performed in quadruplets). (C) CD45+CD14CD20CD3CD11c+Dec205+ cells from
three separate advanced human tumors cultured with PBS or CD40 and poly(I:C) for 24 h. Experiments were performed in duplicate. Error bars,
SEM. *, P < 0.05. Representatives of two independent experiments are shown.

animals with advanced tumors, and therefore are overtly immunostimulatory (Fig. 6 A). In contrast, DCs sorted from the
DLNs of advanced tumors (Fig. 6 A), or dissociated tumor
masses (Fig. 6 B) of advanced tumors, induced minimal proliferative T cell responses. Decreased immunostimulatory activity was further identified in splenic DCs sorted from advanced
tumor-bearing mice, compared with mice challenged only 7 d
earlier in more sensitive ELISPOT analysis (Fig. 6 C).
We then sought to define how early and advanced tumor
microenvironmental DCs influence the capacity of other leukocytes to drive anti-tumor immunity. Remarkably, DCs sorted
from dissociated advanced tumors suppressed tumor-specific
proliferation induced by immunocompetent DCs (Fig. 6,
D and E). We again found that CD11c+ DCs sorted from advanced tumor DLNs elicited comparable immunosuppressive
activity in multiple experiments (Fig. 6 F). In contrast, DCs derived from the DLNs of nascent tumor lesions did not impair
at all the strong expansion of tumor-reactive T cells elicited by
tumor-pulsed BMDCs (Fig. 6 F). Together, these data indicate
that DCs in the microenvironment of nascent tumor lesions are
actively presenting tumor antigens to anti-tumor T cells, which
corresponds with measurable anti-tumor immunity. In contrast,
after tumors have started undergoing exponential growth,
tumor microenvironmental DCs are not only incapable of
inducing significant protective immune responses but they also
become overtly immunosuppressive.
Phenotypically distinct DCs drive both immunosurveillance
and immunological escape during ovarian cancer progression
Corresponding to the differential immunostimulatory capacity
of DCs during tumor initiation and escape, we found significantly lower levels of activating MHCII and CD40 on DCs from
advanced stages of tumor growth (Fig. 7 A). Providing a foundation for the additional immunosuppressive activity of DCs
from exponentially growing tumors, we identified that they
expressed higher levels of tolerogenic PDL-1, compared with
DCs in macroscopically undetectable primordial tumor lesions
and their DLNs (Fig. 7 A). Most importantly, we also identified
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strong (immunosuppressive) Arginase activity in CD11c+ DCs
sorted from advanced solid tumors, which was comparable to
their CD11b+CD11c macrophage/MDSC counterparts but
not in splenic leukocytes (Fig. 7 B). Additionally, we detected
high levels of Arginase activity in CD45+CD14CD20CD3
CD11c+DEC205+ DCs sorted from three separate advanced
human tumors, which could be reduced by incubation with
synergistic immunostimulatory agonists (Fig. 7 C). Therefore,
decreased expression of co-stimulatory mediators and a mixture of immunosuppressive mechanisms converge in DCs from
advanced tumors to abrogate protective immunity.
Together, our data thus far reveal an opposing function for
tumor-associated DCs during the equilibrium versus the escape
phase of tumor progression. To define to what extent phenotypically different DCs truly control tumor progression, we first
brought double (p53/K-ras) transgenic mice to a B6 background.
That resulted in slightly delayed tumor progression (80 vs.
60 d until terminal disease), although tumors still developed
with 100% penetrance. Syngeneic transgenic mice were then
reconstituted with the BM of CD11c-DTR ITGAX mice,
which allows selective temporary ablation of the DC compartment through the administration of diphtheria toxin (Jung et al.,
2002; Zammit et al., 2005). As expected, depletion resulted in
significantly lower proportions of ovarian resident CD11c+ DCs
(Fig. 8 A) within 24 h, compared with chimeric mice which
received PBS. Notably, CD11c+ DC depletion immediately
before tumor challenge accelerated tumor development,
because 75% of mice receiving diphtheria toxin grew palpable tumors within 35 d, compared with only 25% control
mice (Fig. 8 B). Furthermore, a single DC depletion 7 d after
tumor challenge, when immunostimulatory DCs promote
T cell–mediated anti-tumor immunity, resulted in a dramatic
acceleration of tumor progression (Fig. 8, C [top] and D).
In striking contrast, when CD11c+ DCs were depleted at
the beginning of the escape phase (31 d after adenoviral
challenge in this background), elimination of DCs had the
opposite effect and retarded tumor progression, as 100% of
depleted animals had slower growing, smaller tumors (Fig. 8, C
DCs influence ovarian cancer progression | Scarlett et al.
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functionally different at different phases of malignant progression and sufficient to drive both initial immunological
control of tumor growth and accelerated tumor expansion
after equilibrium is broken.

Figure 8. Distinct populations of DCs promote immunosurveillance
and the escape phase of tumor development. (A) FACS analysis of
dissociated ovaries from mice reconstituted with ITGAX-DTR-GFP or WT
BM, 24 h after the i.p. administration of 6 ng/kg of diphtheria toxin.
(B) Proportion of p53/K-ras mice reconstituted with BM from ITGAX-DTR-GFP
mice without palpable tumors at the indicated times after administration
of 6 ng/g of diphtheria toxin (DT) or PBS, 1 d before adenoviral injection
(n = 6mice/group). (C) p53/K-ras mice were reconstituted with BM from
ITGAX-DTR-GFP mice, and DCs were depleted with one dose of 6 ng/kg of
diphtheria toxin (DT) at days 7 (n = 6 mice/group, top), or 31 (n = 10/group,
bottom; two pooled independent experiments) after intrabursal adenovirusCre. PBS (n = 10/group; two pooled independent experiments) was
administered to control mice. (D) Representative size of advanced ovarian
tumors in mice depleted of DCs at early versus advanced stages, compared
with the absence of DC depletion (PBS). Error bars, SEM. *, P < 0.05;
**, P < 0.01. (E) ITGAX-DTR (DT) or WT mice (n = 3/group) were inoculated
intrabursally with 2.5 × 107 plaque-forming units of adenovirus expressing Red-Cherry, and red fluorescence was detected 4 d later. ITGAX-DTR
mice received diphtheria toxin (6 ng/g body weight) 24 h before surgery.
Brightness, contrast and color balance were uniformly adjusted in whole
individual images. Bars, 100 µm. (F) Day 50 tumor growth in p53/Kras
mice challenged with adenovirus-Cre and receiving i.p. PBS or diphtheria
toxin (DT) 7 d later. Shown are representatives of four mice/group.

[bottom] and D). These effects can only be attributed to
phenotypic differences in DCs from different stages of tumor
progression because adenoviral transduction was equally
effective in both the absence and presence of DCs (Fig. 8 E).
In addition, diphtheria toxin had no apparent effect on tumor
progression, as we had previously shown in transplantable
systems (Fig. 8 F; Huarte et al., 2008a). Together, these results
confirm that DCs recruited to ovarian cancer locations are
JEM Vol. 209, No. 3

Tumor cell–derived PGE2 and TGF-1 promote
the immunosuppressive activity of immunocompetent DCs
To gain some insight about microenvironmental signals promoting the immunosuppressive activity of potentially immuno
competent DCs, we quantified an array of cytokines and
chemokines in media conditioned by cultured tumor cells
derived from advanced tumors (UPK10 cells). We identified
that immunosuppressive PGE2 and TGF-1, as well as IL-6,
were secreted by tumor cells at very high levels, and their
production could be at least partially neutralized with specific antibodies (Fig. 9 A). Notably, both tumor-derived PGE2
and mature TGF-1 induced the up-regulation of PD-L1
in (immunocompetent) splenic DCs sorted from day 7 tumorbearing mice because their blockade in tumor-conditioned
media prevented PD-L1 overexpression (Fig. 9 B). Most importantly, tumor-conditioned media promoted the immunosuppressive activity of splenic DCs from early tumor-bearing
mice, which significantly impaired the strong proliferation of
tumor-reactive T cells in response to tumor antigen presented
by BMDCs (Fig. 9 C). Tumor-promoted immunosuppressive
activity required both PGE2 and mature TGF-1 because
when either was neutralized in the tumor-conditioned media,
splenic DCs were incapable of suppressing T cell expansion
(Fig. 9 C). Together, these results indicate that immunosuppressive mediators secreted by tumor cells transform potentially immunocompetent DCs into immunosuppressive
cells. This transformation, which enables the suppression of
anti-tumor T cell–mediated responses, is in part mediated
by PGE2 and TGF-1.
DISCUSSION
Here we have characterized the dynamics of anti-tumor immunity against a new genetic model of inducible ovarian cancer that recapitulates the immune microenvironment of human
tumors. We found that ovarian cancer progresses through a
prolonged period of controlled tumor growth, in which control involves the recruitment of immunostimulatory DCs that
induce measurable T cell–mediated anti-tumor immunity as
early as 7 d after tumor challenge. Coinciding with the expansion of DCs with different (immunosuppressive) activity in the
tumor microenvironment, tumors abrogate protective immunity and start growing in an aggressive manner. Correspondingly,
depletion of DCs, depending on the stage of tumor progression, accelerates tumor progression (early depletion) or inhibits
exponential tumor growth (late depletion).
Previous experimental and clinical evidence shows that
tumor growth can be kept in check for relatively long periods
until tumor cells become edited and escape immune control,
growing into clinically obvious cancers (Koebel et al., 2007;
Schreiber et al., 2011). Eventual escape from anti-tumor
immune surveillance in clinically symptomatic cancers can be
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Figure 9. Tumor cell–derived PGE2 and TGF-1 promote the immunosuppressive activity of DCs. (A) Quantification of PGE2, mature TGF-1,
and IL-6 in media conditioned by tumor cells from advanced (60 d) ovarian cancer specimens, in the presence or the absence of specific neutralizing
antibodies. +BMDCs, BMDCs were incubated for 2 d in tumor-conditioned media before cytokine quantification; cRPMI, RPMI control media; TCmedia,
tumor-conditioned media plus an irrelevant IgG; TCmedia+NeuAb, tumor-conditioned media plus specific neutralizing antibodies. Error bars, SEM. *, P < 0.05.
(B) PD-L1 expression in splenic CD45+CD11c+MHC-II+ DCs sorted from mice carrying early (day 7) tumor lesions, cultured with control versus tumorconditioned media, in the presence or the absence of specific neutralizing antibodies. (C) Splenic DCs (spDCs) sorted from early tumor-bearing mice
were cultured for 48 h in RPMI or tumor-conditioned media (TCMed), in the presence of neutralizing anti-PGE2 or anti–TGF-1 antibodies (NeuAb), or an
irrelevant IgG. These cultured DCs were then incubated with tumor-pulsed BMDCs plus CFSE-labeled tumor-reactive T cells, obtained as in Fig. 6 A (1:1:1 ratio).
Unpulsed BMDCs were added to control wells. The panel shows representative histograms of the proliferation of tumor-reactive T cells under different
conditions. Representatives of two independent experiments are shown.

attributed to various complementary mechanisms. Originally,
the cancer immunoediting hypothesis proposed the progressive loss of immunogenicity by tumor cells as the fundamental
driver of accelerated tumor growth. This implies that tumor
immunogenicity is primarily sculpted by plastic tumor cells
evolving to lose recognizable epitopes. More recently, the
model has evolved to include tumor-induced immunosuppression as a contributor to this process, but the importance
of individual tolerogenic mechanisms in different tumors remains unclear (Schreiber et al., 2011). Our results show that
both equilibrium and exponential ovarian cancer growth are
driven independently by the presence of phenotypically dissimilar DCs in the tumor microenvironment. Advanced
tumors remain immunogenic because they induce significant
proliferative responses in T cells from early tumors. However,
the capacity of tumor-specific T cells to react against the same
antigen was diminished at advanced stages, which supports
previous observations in transplantable models (Nagaraj et al.,
2007). Concomitantly, DCs at draining lymphatic and tumor
sites are transformed during tumor progression into a cell
type that not only presents antigens ineffectively but also actively suppresses T cell responses. Most importantly, protective
responses could be restored by depleting this immunosuppressive component, which is distinctively recruited during
the phase when tumors spontaneously escape immune control.
Such depletion prevents accelerated tumor growth without
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any direct intervention on the tumor cell. Although we cannot exclude that tumor-associated DCs also promote other
important tumorigenic mechanisms (e.g., angiogenesis), our
study uncovers the recruitment of immunosuppressive DCs,
rather than loss of immunogenicity, as the principal mechanism
driving the transition from equilibrium to expansive progression
in ovarian cancer. In addition, our data provide a mechanistic
rationale for targeting regulatory DCs as the characteristic
product of the pathological myelopoiesis orchestrated by
advanced ovarian cancers.
Importantly, similar to tumor development in adult humans,
our model develops in healthy adult mice without active
mutations during embryonic development. We found that
breaking equilibrium between tumor growth and immune
control to achieve aggressive tumor growth is significantly
challenging in this context and is indicated by the necessity of
two simultaneous mutation events for malignancy. In any
case, despite the importance of p53, our work supports previous studies which demonstrate that its homozygous ablation
does not immediately result in any obvious phenotype, and
tumors require >7 mo to advance even after the addition of
a second mutation, different from KRAS (Flesken-Nikitin
et al., 2003). Overall, our results suggest that even if primordial
tumor lesions can be established, tumor microenvironmental
leukocytes prevent their unrelenting growth for a relatively
prolonged equilibrium phase. Only when the inflammatory
DCs influence ovarian cancer progression | Scarlett et al.
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infiltrate undergoes precise phenotypic and quantitative changes
does tumor growth become exponential and thus clinically apparent.
MATERIALS AND METHODS
Animals and tissues. WT C57BL/6 mice were procured from the National
Cancer Institute or The Jackson Laboratory, under Institutional Animal Care and
Use Committee approval. Stage III–IV human ovarian carcinoma specimens
were procured through Research Pathology Services at Dartmouth-Hitchcock
Medical Center under institutional approval (CPHS17702). Single cell suspensions or cDNA were generated as we previously described (Huarte et al., 2008b).
The primary mouse cell line, UPK10, was generated by culturing a mechanically
dissociated B6 LSL-K-rasG12D/+p53loxP/loxP primary ovarian tumor mass. Tumor
cells were passaged a total of 10× and lead to terminal tumor masses 28 d after
i.p. injection in WT animals. HOSEpiC are epithelial cells from healthy ovaries
cryopreserved either at primary or passage one cultures (ScienCell Research).
Generation of transgenic mice. To generate the LSL-K-rasG12D/+p53loxP/loxP
model, we used Krastm4Tyj and Trp53tm1Brn mice (Jackson et al., 2001; Jonkers
et al., 2001), obtained from the NCI Mouse Models of Human Cancers
Consortium. For the indicated experiments, mice were brought to a
C57BL/6 background.
Chimera generation and antibody-mediated depletion. BM cells (10 ×
106) isolated from ITGAX DTR-GFP mice were injected intravenously into B6
K-rasG12D/+p53loxP/loxP after undergoing lethal doses of gamma irradiation, as we
previously described (Huarte et al., 2008a). Mice were checked for complete reconstitution by identifying GFP+CD45+CD11c+ cells in peripheral blood 6 wk
after reconstitution. ITGAX-DTR (DT) or WT mice (n = 3/group) were inoculated intrabursally with 2.5 × 107 plaque-forming units of adenovirus expressing
Red-Cherry (Gene Transfer Vector Core, University of Iowa).
CD8 T cells were depleted through intraperitoneal administration of rat
anti–mouse CD8 antibodies (clone# YTS 169.4; BioXCell), 2 d before intrabursal administration of 500 µg adenovirus-Cre. Injections were repeated
at days 5, 12, and 19 (250 µg each). Control mice received a rat IgG2b isotype control (clone# LTF-2; BioXCell).
Proliferation and suppression assays. For T cell proliferation assays, day 7
BMDCs, generated as previously described (Scarlett et al., 2009), were cultured
overnight with either freeze-thawed lysed UPK10 or dissociated primary tumors.
BMDCs were added to cultures of CFSE (Invitrogen)-labeled T cells at a 10:1
ratio and were analyzed 3 d later by flow cytometry. For DC proliferation assays
(Fig. 6 A, schematic), Pan T cell isolation (Miltenyi Biotec) was performed using
spleens taken from p53/K-ras animals with advanced (>50 d after AdvCre
injection) tumors. CD3+ T cells were then cultured for 4–5 d with tumorpulsed BMDCs as described at a 10:1 ratio to generate tumor-specific T cells.
Tumor-specific T cells were then CFSE labeled and added to V-bottom 96-well
plates which contained sorted DCs (10:1 ratio). Cultures were analyzed by flow
cytometry 5 d later. For the suppression assay (Fig. 6 C, schematic), tumor-pulsed
BMDCs were added to CFSE-labeled tumor-specific T cells (1:1), followed by
addition of unpulsed BMDCs or sorted DCs (1:1:1 ratio) in V-bottom 96-well
plates. Analyses were performed 3 d later.
Neutralization assays. PGE2 (Cayman Chemical) and mature TGF-1 and
IL-6 (both eBioscience) were quantified by ELISA in media conditioned
for 2 d by >90% confluent UPK10 tumor cells. When indicated, neutralizing
antibodies against mouse PGE2 (7 µg/ml; 2B5; Cayman Chemical), TGF-1
(5 µg/ml; 2Ar2; Abcam) or IL-6 (4 µg/ml; PeproTech) were added to the
media. Goat anti–mouse IgG (Jackson ImmunoResearch Laboratories, Inc.)
was used as a control.
Histological analysis. For frozen tissue, organs of mice were collected and embedded in Tissue-Tek OCT. For paraffin-embedded tissue, organs were fixed in
4% formaldehyde overnight at 4°C. Fixed sections (8 µm) were then made from
frozen or paraffin-embedded tissue blocks. For analysis of tumor histological type,
JEM Vol. 209, No. 3

pan Cytokeratin (AE1+AE3) 1:50 dilution, smooth muscle actin (SMA; EP184E)
1:500 dilution, Desmin (Y266) 1:500 dilution, Cytokeratin 8 (ab59400) 1:250
dilution, and Vimentin (RB202) 1:200 dilution were purchased from Abcam and
immunohistochemical analyses were performed by the Dartmouth Pathology
Translational Research Core (Lebanon, NH). For immunohistochemistry of
leukocytes, tissues were blocked using -CD32, followed by staining with anti–
mouse biotinylated CD45 (104), MHCII (M5/114.15.2), or APC-conjugated
Dec205 (NLDC-145; all obtained from BioLegend). Completion of immunohistochemical procedure was performed according to the manufacturer’s instructions (Vector Laboratories). Slides were then viewed at various magnifications
using a fluorescence microscope (Nikon) and the NIS-Element Imaging software.
Flow cytometry. Flow cytometry was performed on a FACSCanto (BD). Sorting was performed on a FACSAria sorter (BD). Anti–mouse antibodies: CD45
(30-F11), CD11b (M1/70), DEC205 (NLDC-145), F4/80 (BM8), GR1 (RB6-8C5),
CD3 (145-2C11), CD8 (YTS156.7.7), CD8 (53–6.7), CD4 (GK1.5),
CD25 (PC61.5), and PDL-1 (10F.9G2; all obtained from BioLegend); and Foxp3
(FJK-16s), CD11c (N418), and MHC-II (NIMR-4; eBioscience). Anti–human
antibodies: CD45 (H130), DEC205 (HD30), CD11c (3.9), CD3 (OKT3),
CD11b (ICRF44), HLA-DR (L243), CD14 (HCD14), and CD20 (2H7; all
obtained from BioLegend). The purity of FACS-sorted populations was >90%.
Quantitative real-time PCR and sequencing. Messenger RNA copy number of various loci was assessed by quantitative real-time PCR using an Real
Time PCR Machine (Applied Biosystems). Primers for RT-PCR experiments
to detect human K-ras expression using SYBR green: Kras forward, 5-TGT
GGACGAATATGATCCAACAA-3; and Kras reverse, 5-TCCTCATGTA
CTGGTCCCTCATT-3. Primers for mouse and human GAPDH expression
using TaqMan: GAPDH forward, 5-CCTGCACCACCAACTGCTTA-3;
GAPDH reverse, 5-AGTGATGGCATGGACTGTGCT-3; and probe
(FAM/TAMRA), 5-CCTGGCCAAGGTCATCCATGACAACTTT-3.
Cytokine/chemokine detection. Sorted tumor-associated cells from
either p53/K-ras mice or Stage III–IV human ovarian carcinoma specimens
were stimulated for 4 h with 50 ng PMA/1 µg/ml ionomycin in complete
RPMI containing 10% FBS. Supernatants were used for cytokines and chemokines using a human or mouse Custom-Plex panel cytokine assay (Bio-Rad
Laboratories), according to the manufacturer’s instructions.
Arginase activity assay. Cells from either p53/K-ras mice (tumor and
spleens) or Stage III–IV human ovarian carcinoma specimens were sorted.
Quantitative colorimetric arginase determination was performed using an
Arginase Activity detection kit (BioAssay Systems). In brief, 0.05–0.25 × 106
cells were washed and lysed for 10 min in 50 µl of 10 mM Tris-HCl, pH 7.4,
containing 0.15 mM pepstatin A, 0.2 mM leupeptin, and 0.4% (vol/vol)
Triton X-100. Supernatants from lysates were then used to complete the
assay according to the manufacturer’s instructions. For human analysis, we
cultured cells with agonistic CP-870,893 CD40 monoclonal antibody and
poly (I:C) as previously described (Scarlett et al., 2009). We obtained the
CP-870,893 monoclonal antibody from Pfizer.
ELISPOT. Total or sorted cells were obtained from dissociated spleens,
renal DLNs, or tumors of p53/K-ras or WT controls. T cells were then cocultured for 72 h in coated and blocked ELISPOT plates, in a 10:1 ratio
among day 7 BMDC or sorted DC, which were previously pulsed (4 h) with
freeze-thawed lysed UPK10 cells or resected primary tumor (10 DC/1 tumor
cell). All cultures were maintained in complete RPMI containing 10% FBS.
Analysis was then continued according to manufacturer’s protocol (IFN-,
eBioscience; and Granzyme B, R&D Systems).
Immunoblotting. TRIzol reagent (Invitrogen) was used to obtain protein
from either stage III or IV human solid tumor specimens. In brief, frozen tissues
were cut into tiny pieces, and then added to complete RPMI where they
were further macerated using the end of a syringe’s plunger. The dissociated
tissues were spun and the pellets were added to TRIzol, and the completion
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of the protein extraction was performed according to the manufacturer’s
instruction. Proteins were diluted in 7 µl Laemmli buffer, boiled, loaded
onto a 12% Ready Gel Tris-HCL gel (Bio-Rad Laboratories), transferred
to a nitrocellulose membrane, blocked, and incubated with the indicated
primary Ab. Immunoreactive bands were developed using horseradish
peroxidase–conjugated secondary Abs (Bio-Rad Laboratories) and chemiluminescent substrate (GE Healthcare). Human KRAS, -actin, and -tubulin
were detected using a mouse anti–human mAb (clone no. ab55391), rabbit
anti–human (ab8227), and goat anti–human (ab21057) antibodies, respectively
(all from Abcam).
Statistical analyses. Differences between the means of experimental groups
were analyzed using the Mann-Whitney or the 2 test. Survival was analyzed
with the Log-rank test, both using Prism 4.0 software (GraphPad Software).
Proliferation indices, defined as the mean number of cell divisions that the responding cells underwent, were calculated using FlowJo software (Tree Star).
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